Work

Abstract 4137311: Inhibition of IL-33 by tozorakimab in patients with diabetic kidney disease: Cardiovascular insights from FRONTIER-1

Year: 2024

Type: conference-abstract

Source: Circulation

DOI: 10.1161/circ.150.suppl_1.4137311

Authors: Viknesh Selvarajah, Kaisa Maki-Petaja, Stefano Bartesaghi, Elena Surkova, Andrea Vavere, Deepa Arya, Dennis Brooks, Daniel Grice, Yan Zhu, Roberto Pecoits-Filho, Hiddo Lambers Heerspink, Alexis Hofherr

Institutions: AstraZeneca (United Kingdom), AstraZeneca (Sweden), AstraZeneca (United States), Arbor Research Collaborative for Health, UNSW Sydney, The George Institute for Global Health

Language: English

Topic: IL-33, ST2, and ILC Pathways

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404322776

Cites:

Cited by: 1

Related to: 10